Table 3. Demographics of enrolled patients.
| Buparlisib (BKM120) | Dovitinib (TKI258) | Binimetinib (MEK162) | Encorafenib (LGX818) | Sonidegib (LDE225) | BGJ398 | Ceritinib (LDK378) | Ribociclib (LEE011) | Total | |
|---|---|---|---|---|---|---|---|---|---|
| Patients treated, n | 146 | 80 | 110 | 12 | 10 | 84 | 47 | 106 | 595 |
| Age, median, years | 60 | 60 | 62 | 58 | 67 | 61 | 58 | 63 | 61 |
| Male, % | 42 | 50 | 38 | 42 | 40 | 44 | 53 | 47 | 44 |
| White, % | 89 | 86 | 86 | 92 | 60 | 88 | 81 | 85 | 86 |
| ECOG PS, %a | |||||||||
| 0 | 37 | 48 | 35 | 58 | 20 | 25 | 40 | 34 | 36 |
| 1 | 63b | 53 | 65 | 42 | 80 | 75 | 60 | 66 | 64b |
| Prior lines of therapy, median (range), nc | 3 (1-13) | 4 (0-14) | 3 (0-16) | 2 (0-7) | 4 (1-11) | 3 (0-14) | 3 (0-14) | 3 (0-19) | 3 (0-19) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.
aMay not equal 100% due to rounding.
bIncludes 1 patient with ECOG PS of 2 at baseline.
cOnly prior drug therapies are included.